Q-omics provides the consensus-scored EFCAB5 profile across patient tissues and cancer cell-line models. EFCAB5 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, EFCAB5 is differentially expressed in 13, with the highest sampling consensus in KICH. Additionally, EFCAB5 RNA expression shows 19,907 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight MESO, KICH, and UVM as cancer lineages where EFCAB5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for EFCAB5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes EFCAB5 survival associations across molecular data types. EFCAB5 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible EFCAB5 RNA expression–survival associations across cancer types. High EFCAB5 expression shows unfavorable associations in MESO, ACC and SKCM, but favorable associations in BLCA, READ and UCS. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for EFCAB5 RNA expression.
This table summarizes EFCAB5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for EFCAB5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. EFCAB5 shows lower tumor expression in KICH, KIRC, THCA, COAD and LUSC and higher tumor expression in LIHC. The KICH box plot shows higher EFCAB5 RNA expression in normal versus tumor tissue (log2 FC = −0.461, t-test p < 0.001).
This table shows molecular features associated with EFCAB5 in patient tissues and cancer cell lines. In patient samples, EFCAB5 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, EFCAB5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and BLOOD_Leukemia.
